Skip to main content
. 2024 Jul 24;12(8):1654. doi: 10.3390/biomedicines12081654

Table 1.

Patient characteristics of the whole cohort according to antidiabetic medication and statin use.

Metformin Insulin Other ADM Statin
Yes (%) No (%) Yes (%) No (%) Yes (%) No (%) Yes (%) No (%) Total (%)
Total 885 (100) 498 (100) 533 (100) 850 (100) 749 (100) 634 (100) 529 (100) 854 (100) 1383 (100)
Sex
Male 733 (83) 376 (76) 426 (80) 683 (80) 598 (80) 511 (81) 435 (82) 674 (79) 1109 (80)
Female 152 (17) 122 (24) 107 (20) 167 (20) 151 (20) 123 (19) 94 (18) 180 (21) 274 (20)
Education
Basic 275 (31) 149 (30) 178 (33) 246 (29) 235 (31) 189 (30) 168 (32) 256 (30) 424 (31)
Intermediate 338 (38) 207 (42) 206 (39) 339 (40) 281 (38) 264 (42) 213 (40) 332 (39) 545 (39)
Higher 272 (31) 142 (29) 149 (28) 265 (31) 233 (31) 181 (29) 148 (28) 266 (31) 414 (30)
Follow-up time (years)
Median 0.5 0.3 0.4 0.4 0.4 0.4 0.5 0.3 0.4
Interquartile range 0.1–1.5 0.04–1.0 0.07–1.2 0.09–1.3 0.08–1.3 0.09–1.2 0.1–1.4 0.06–1.2 0.08–1.3
Duration of diabetes (years)
Median 9.9 9.0 13.7 7.7 10.4 8.5 11.4 8.6 9.6
Interquartile range 6.1–14.9 5.1–15.9 9.1–18.1 4.4–11.7 6.9–15.2 4.3–15.2 7.2–16.7 5.0–13.5 5.6–15.2
Hepatitis
Yes 55 (6) 48 (10) 47 (9) 56 (7) 50 (7) 53 (8) 34 (6) 69 (8) 103 (7)
No 830 (94) 450 (90) 486 (91) 794 (93) 699 (93) 581 (92) 495 (94) 785 (92) 1280 (93)
Cirrhosis
Yes 190 (21) 144 (29) 152 (29) 182 (21) 170 (23) 164 (26) 91 (17) 243 (28) 334 (24)
No 695 (79) 354 (71) 381 (71) 668 (79) 579 (77) 470 (74) 438 (83) 611 (72) 1049 (76)
Age at HCC diagnosis (years)
Median 71 72 71 72 72 71 72 71 72
Interquartile range 66–78 65–80 65–77 66–79 66–79 65–78 67–78 65–78 66–78
Stage of HCC
Local 173 (20) 119 (24) 105 (20) 187 (22) 167 (22) 125 (20) 97 (18) 195 (23) 292 (21)
Advanced 228 (26) 135 (27) 153 (29) 210 (25) 204 (27) 159 (25) 122 (23) 241 (28) 363 (26)
Unknown 484 (55) 244 (49) 275 (52) 453 (53) 378 (50) 350 (55) 310 (59) 418 (49) 728 (53)

ADM = antidiabetic medication, HCC = hepatocellular carcinoma.